Related Experiment Video

Updated: Mar 15, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban

Jaime Masjuan1,2,3, Alicia DeFelipe1

  • 1a Servicio de Neurologia , Hospital Universitario Ramon y Cajal , Madrid , Spain.

The International Journal of Neuroscience
|September 3, 2016
PubMed

Insights

Edoxaban effectively prevents stroke in atrial fibrillation patients, including those with prior stroke. This anticoagulant shows similar stroke reduction to warfarin but with a significantly lower risk of bleeding events, especially intracranial hemorrhage.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Patients with atrial fibrillation (AF) and a history of stroke or transient ischemic attack (TIA) face a high risk of recurrent events.
  • Secondary stroke prevention with oral anticoagulants is crucial, with guidelines favoring target-specific oral anticoagulants (TSOACs) over vitamin K antagonists (VKAs).
  • Underutilization of appropriate antithrombotic therapy in AF patients with prior stroke may stem from concerns about bleeding risks, including hemorrhagic transformation.

Purpose of the Study:

  • To review and update evidence on the use of edoxaban for secondary stroke prevention in non-valvular atrial fibrillation (NVAF) patients.
  • To evaluate edoxaban's efficacy and safety profile in managing NVAF patients with a history of stroke or TIA.

Main Methods:

  • Analysis of data from the ENGAGE AF-TIMI 48 trial, comparing edoxaban 60 mg with warfarin.
  • Assessment of stroke risk reduction and bleeding events, including intracranial hemorrhage (ICH).
  • Evaluation of treatment outcomes stratified by the presence or absence of prior stroke or TIA.

Main Results:

  • Edoxaban 60 mg and warfarin demonstrated comparable efficacy in reducing stroke risk.
  • Edoxaban exhibited a significantly lower risk of bleeding events compared to warfarin, particularly ICH.
  • These findings were consistent regardless of whether patients had a prior stroke or TIA.

Conclusions:

  • Edoxaban is a safe and effective option for both primary and secondary stroke prevention in patients with NVAF.
  • The favorable bleeding profile of edoxaban, especially reduced ICH risk, supports its use in high-risk populations like those with prior stroke.
  • Edoxaban offers a valuable therapeutic option for optimizing antithrombotic management in NVAF patients requiring secondary stroke prevention.

Keywords:
ENGAGE AF-TIMI 48anticoagulationatrial fibrillationedoxabansecondary prevention

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
453
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
618
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
356
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
614